rss
J Neurol Neurosurg Psychiatry 2008;79:1027-1031 doi:10.1136/jnnp.2007.139345
  • Research paper

Effects of fluoxetine on disease activity in relapsing multiple sclerosis: a double-blind, placebo-controlled, exploratory study

  1. J P Mostert1,
  2. F Admiraal-Behloul2,
  3. J M Hoogduin3,
  4. J Luyendijk2,
  5. D J Heersema1,
  6. M A van Buchem2,
  7. J De Keyser1
  1. 1
    Department of Neurology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands
  2. 2
    Department of Radiology, Leiden University Medical Centre, Leiden, The Netherlands
  3. 3
    NeuroImaging Centre, University of Groningen, Groningen, The Netherlands
  1. Dr Jop Mostert, Department of Neurology, University Medical Centre Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands; j.p.mostert{at}neuro.umcg.nl
  • Received 12 November 2007
  • Revised 9 February 2008
  • Accepted 18 February 2008
  • Published Online First 1 May 2008

Abstract

Background: Suppressing the antigen-presenting capacity of glial cells could represent a novel way of reducing inflammatory activity in multiple sclerosis (MS).

Aims: To evaluate the effects of fluoxetine on new lesion formation in patients with relapsing MS.

Methods: In a double-blind, placebo-controlled exploratory study, 40 non-depressed patients with relapsing remitting or relapsing secondary progressive MS were randomised to oral fluoxetine 20 mg or placebo daily for 24 weeks. New lesion formation was studied by assessing the cumulative number of gadolinium-enhancing lesions on brain MRI performed on weeks 4, 8, 16 and 24.

Results: Nineteen patients in both groups completed the study. The mean (SD) cumulative number of new enhancing lesions during the 24 weeks of treatment was 1.84 (2.9) in the fluoxetine group and 5.16 (8.6) in the placebo group (p = 0.15). The number of scans showing new enhancing lesions was 25% in the fluoxetine group versus 41% in the placebo group (p = 0.04). Restricting the analysis to the past 16 weeks of treatment showed that the cumulative number of new enhancing lesions was 1.21 (2.6) in the fluoxetine group and 3.16 (5.3) in the placebo group (p = 0.05). The number of patients without enhancing lesions was 63% in the fluoxetine group versus 26% in the placebo group (p = 0.02).

Conclusions: This proof-of-concept study shows that fluoxetine tends to reduce the formation of new enhancing lesions in patients with MS. Further studies with this compound are warranted.

Trial registration: Number: ISRCTN65586975

Footnotes

  • Competing interests: None.

  • Funding: This study was supported by a grant from “Multiple Sclerosis anders”, Rhôneweg 6, 1043 AH, Amsterdam, The Netherlands.

This Article

  1. Abstract
  2. Full text
  3. PDF
  4. All versions of this article:
    1. jnnp.2007.139345v1
    2. 79/9/1027 most recent

Responses

  1. Submit a response
  2. No responses published

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

BMJ Careers - Latest neurology and neurosurgery jobs